ACADIA Pharmaceuticals (FRA:DR6) Other Net Income (Loss) : €-0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Other Net Income (Loss)?

ACADIA Pharmaceuticals's Other Net Income (Loss) for the three months ended in Mar. 2024 was €0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.0 Mil.

ACADIA Pharmaceuticals's quarterly Other Net Income (Loss) increased from Sep. 2023 (€-0.0 Mil) to Dec. 2023 (€0.0 Mil) and increased from Dec. 2023 (€0.0 Mil) to Mar. 2024 (€0.0 Mil).

ACADIA Pharmaceuticals's annual Other Net Income (Loss) increased from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€0.0 Mil) but then declined from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil).

ACADIA Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for ACADIA Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Other Net Income (Loss) Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

ACADIA Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

ACADIA Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.0 Mil.

ACADIA Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals (FRA:DR6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

ACAD:USA

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia-pharm.com

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (FRA:DR6) Headlines

No Headlines